Research Projects & Grants

  • Compassionate Use of Sparsentan, a Dual-Acting Antagonist of Both the Endothelin A and Angiotensin 11 Subtype 1 Receptors in Patient with Nephrotic Syndrome secondary to Minimal Change, Role: PI, Status: Approved

For Profit Organization

  • Hemoglobin Maintenance In Pediatric ESRD Patients By Ferric Pyrophosphate Citrate (FPC), Role: Investigator, Rockwell Medical Inc., (05/2022 - 05/2023) Status: Completed
  • An open-label, single-arm, multicenter study to ascertain the optimal starting dose of Mircera® given subcutaneously for the maintenance treatment of Anemia in pediatric patients with chronic kidney disease on dialysis or not yet on dialysis, Role: Investigator, Hoffmann-La Roche Inc., (04/2021 - 04/2022) Status: Completed
  • Treatment of drug-resistant adult and pediatric primary focal segmental glomerulosclerosis using the Liposorber LA-15 System, Role: PI, Kaneka Medical America LLC, (03/2025 - 03/2026) Status: Approved

Internal

  • North American Pediatric Renal Trials Collaborative Studies (NAPRTCS), Role: Investigator, LLU Dept. of Pediatrics, (06/2024 - 06/2025) Status: Approved
  • Rituximab use in nephrotic syndrome, Role: PI, LLU Dept. of Pediatrics, (04/2016) Status: Completed
  • Calcium receptor activating mutation in a pediatric patient, Role: PI, LLU Dept. of Pediatrics, (01/2016) Status: Completed
  • A prospective study of citrate based dialysate in pediatric patients receiving intermittent hemodialysis, Role: Investigator, LLU Dept. of Pediatrics, (04/2015 - 04/2016) Status: Completed

Non-Profit Organization

  • Chronic Kidney Disease in Children (CKiD), Role: PD/PI, Children's Hospital Philadelphia, (09/2023 - 07/2025) Status: Awarded
  • Chronic Kidney Disease in Children Prospective Cohort Study (CKid), Role: Principal Investigator, Children's Hospital Philadelphia, (08/2017 - 07/2023) Status: Awarded

Other Research

  • Principal Investigator (LLU Site). Treatment of Drug Resistant Primary Foca Segmental Glomerulosclerosis using the Liposorber LA-System. Post Approval Study Plan. Kaneka Pharma America LLC. ClinicalTrials. gov identifier NCT02235857. (07/2016 - Present)